{
    "2018-06-25": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Merck (MRK) Presents New Data from Januvia Diabetes Studies",
                "features": {
                    "keywords": [
                        "Merck",
                        "Januvia",
                        "diabetes",
                        "studies"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Lilly Wins Favorable Ruling From U.S. Court in Alimta Row",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Alimta",
                        "favorable ruling",
                        "court"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Lilly's Jardiance meets main goal of two diabetes trials",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Jardiance",
                        "diabetes",
                        "trials"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes",
                "features": {
                    "keywords": [
                        "Boehringer Ingelheim",
                        "Lilly",
                        "empagliflozin",
                        "Phase III",
                        "type 1 diabetes"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "First-ever Study of Lilly's HumulinÂ® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Humulin",
                        "A1C",
                        "Type 2 Diabetes"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Phase 3",
                        "migraine",
                        "cluster headache"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Eli Lilly: Humulin R U-500 Administered In Insulin Pump Shows Improved A1C",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Humulin",
                        "A1C",
                        "insulin pump"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Boehringer Ingelheim & Eli Lilly: Empagliflozin Trials Meet Primary Endpoint",
                "features": {
                    "keywords": [
                        "Boehringer Ingelheim",
                        "Eli Lilly",
                        "empagliflozin",
                        "trials"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "Eli Lilly To Present Phase 3 Data For Galcanezumab, Lasmiditan - Quick Facts",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Galcanezumab",
                        "Lasmiditan",
                        "Phase 3"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}